本报告导读：公司运营持续提效，2025 年预计迎来扭亏。泽布替尼高速放量，美国新患份额跃居第一。研发管线步入加速收获期，有望迎来密集催化。维持“增持”评级。投资要点：维持“增持”评级。公司 2024 年实现产品收入 37.8 亿美元，同比+72.6%；其中2024Q4 实现产品收入11.2 亿美元，同比+77.3%，呈高速增长态势。随着公司运营效率持续提高，产品收入增长超过经营费用增长，非GAAP...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.